Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Among authors: gremese e. Ann Rheum Dis. 2023 Apr;82(4):496-506. doi: 10.1136/ard-2022-222879. Epub 2022 Dec 13. Ann Rheum Dis. 2023. PMID: 36600178 Free PMC article.
Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, Benvenuto R, Fedele AL, Federico F, Ferraccioli G, Gremese E. Alivernini S, et al. Among authors: gremese e. Ann Rheum Dis. 2017 Jul;76(7):1228-1236. doi: 10.1136/annrheumdis-2016-210424. Epub 2017 Jan 24. Ann Rheum Dis. 2017. PMID: 28119289 Free PMC article.
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.
Smolen JS, Siebert S, Korotaeva TV, Selmi C, Bergmans P, Gremese E, Joven-Ibáñez B, Katsifis G, Noël W, Nurmohamed MT, Richette P, Sfikakis PP, de Vlam K, Theander E, Gossec L. Smolen JS, et al. Among authors: gremese e. Ann Rheum Dis. 2021 Nov;80(11):1419-1428. doi: 10.1136/annrheumdis-2021-220263. Epub 2021 Jun 23. Ann Rheum Dis. 2021. PMID: 34162594 Free PMC article.
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Theander E, Smolen JS. Gossec L, et al. Among authors: gremese e. Ann Rheum Dis. 2022 Jun;81(6):823-830. doi: 10.1136/annrheumdis-2021-221640. Epub 2022 Feb 24. Ann Rheum Dis. 2022. PMID: 35210262 Free PMC article.
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Gremese E, Ciccia F, Selmi C, Cuomo G, Foti R, Matucci-Cerinic M, Conti F, Fusaro E, Guggino G, Iannone F, Delle Sedie A, Perricone R, Idolazzi L, Moscato P, Theander E, Noël W, Bergmans P, Marelli S, Gossec L, Smolen JS; Italian PsABio study. Gremese E, et al. Clin Exp Rheumatol. 2023 Mar;41(3):735-743. doi: 10.55563/clinexprheumatol/j33pjt. Epub 2022 Oct 12. Clin Exp Rheumatol. 2023. PMID: 36226614 Free article.
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Van Kuijk AWR, Nurmohamed MT, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Sharaf M, Noël W, Theander E, Smolen JS, Gossec L, van der Horst-Bruinsma IE. Van Kuijk AWR, et al. Among authors: gremese e. Rheumatology (Oxford). 2023 Oct 3;62(10):3382-3390. doi: 10.1093/rheumatology/kead089. Rheumatology (Oxford). 2023. PMID: 36810788 Free PMC article.
293 results